NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC Patents valid through 2038 Clinical topline results from Phase 2b ALS trial expected in H2 2023

NeuroSense Granted Patents in Europe,

Japan, and Israel for its ALS Drug PrimeC

CAMBRIDGE, Mass., Sept. 19, 2023 /PRNewswire/ -- NeuroSense

Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today

announced that the European, Japan, and Israel Patent Offices have granted the Company a key patent relating to "Compositions comprising

an anti-inflammatory drug and a dicer activator for use in treatment of neuronal diseases." The patents relate to NeuroSense's

unique fixed-dose combination of ciprofloxacin and celecoxib, two U.S. Food and Drug Administration (FDA) approved drugs that are the

active ingredients in PrimeC, the Company's lead drug candidate for treating Amyotrophic Lateral Sclerosis (ALS).

Corresponding patents have been issued in the U.S., Canada, and Australia

and are valid through 2038, subject to appropriate maintenance. Additional patent applications relating to the novel formulation of PrimeC

and methods for the treatment of other neurodegenerative diseases using NeuroSense's platform of combination therapies including

StabiliC and CogniC are pending as well.

"We are pleased to receive this most recent patent grant in Europe,

Japan, and Israel, which adds to our growing IP estate as we expect the clinical read-out from our PARADIGM Phase 2b study towards

year's end. ALS remains a pressing unmet need, and our unwavering commitment to advancing our program, supported by robust intellectual

property, underscores our dedication to delivering an effective therapy for individuals battling ALS." stated Alon Ben-Noon, NeuroSense's

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company

focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes

that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease,

among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available

for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of

related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

For additional information, we invite you to visit our website and

Forward-Looking Statements

This press release contains "forward-looking statements"

that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press

release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words

such as "anticipate," "believe," "contemplate," "could," "estimate," "expect,"

"intend," "seek," "may," "might," "plan," "potential," "predict,"

"project," "target," "aim," "should," "will" "would," or the negative

of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements

are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that

are difficult to predict and include statements regarding the timing of top-line results of, and the results of, the PARADIGM clinical

trial. Further, forward-looking statements are subject to a number of risks and uncertainties as a result of which actual results could

differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include a delay in the

reporting of top-line results from PARADIGM clinical trial; greater than anticipated costs and expenses; the potential for PrimeC to safely

and effectively target ALS; preclinical and clinical data for PrimeC; the timing of current and future clinical trials, timing for reporting

data; the nature, strategy and focus of the company and further updates with respect thereto; the development and commercial potential

of any product candidates of the company; and other risks and uncertainties set forth in NeuroSense's filings with the Securities

and Exchange Commission (SEC), including NeuroSense's Annual Report on Form 20-F filed with the SEC on March 22, 2023. Forward-looking

statements contained in this announcement are made as of this date, and NeuroSense Therapeutics Ltd. undertakes no duty to update such

information except as required under applicable law.

Logo - https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

For further information: Email: info@neurosense-tx.com, Tel: +972 9